Loading…

CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross‐sectional descriptive trial

Background Melanoma is the most lethal skin cancer, and its incidence has increased worldwide. About 10% of cases are classified as hereditary melanoma (HM). CDKN2A and CDK4 are the major high‐risk genes. Families are also more prone to develop pancreatic cancer, and different forms of oncological s...

Full description

Saved in:
Bibliographic Details
Published in:International journal of dermatology 2023-08, Vol.62 (8), p.1060-1066
Main Authors: Arnaut, Joyce R. M. B., Guimarães, Isabella dos S., Santos, Anna Cláudia E., Rodrigues, Elizângela M., Machado, Jorge R. da S., Melo, Andreia C.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3532-db5021f8f4d2253f3136bd0618895f62dfe1e2ae889794a4ff87021a545dde573
cites cdi_FETCH-LOGICAL-c3532-db5021f8f4d2253f3136bd0618895f62dfe1e2ae889794a4ff87021a545dde573
container_end_page 1066
container_issue 8
container_start_page 1060
container_title International journal of dermatology
container_volume 62
creator Arnaut, Joyce R. M. B.
Guimarães, Isabella dos S.
Santos, Anna Cláudia E.
Rodrigues, Elizângela M.
Machado, Jorge R. da S.
Melo, Andreia C.
description Background Melanoma is the most lethal skin cancer, and its incidence has increased worldwide. About 10% of cases are classified as hereditary melanoma (HM). CDKN2A and CDK4 are the major high‐risk genes. Families are also more prone to develop pancreatic cancer, and different forms of oncological surveillance are recommended. Objectives Describe the prevalence of CDKN2A/CDK4 germline mutations in melanoma‐prone patients and their phenotypic and histopathological features. Methods A total of 69 patients meeting the clinical criteria for HM were included in this cross‐sectional descriptive study. Amplification by PCR and genomic sequencing were used. The variants were classified according to American College of Medical Genetics (ACMG) criteria. Results The mean age at first diagnosis of melanoma was 44.8 years (SD ± 17.83). Most patients had phototype II (44.9%), more than 50 melanocytic nevi (76.8%), atypical nevus syndrome (72.5%), history of sunburn (76.8%), and multiple primary melanomas without a family history of this tumor (74.3%). Two hundred melanomas were observed. Most tumors had a Breslow index ≤1.0 mm (84.5%), location in the trunk (60.5%), and superficial spreading histological subtype (22.5%). Four variants were found in CDKN2A exons in seven patients (c.305C>A, c.26T>A, c.361G>A e c.442G>A), two variants in the 5′UTR region in five patients (c.‐25C>T and c.‐33G>C), and two variants in the 3′UTR region in 21 patients (c.*29C>G and c.*69C>T). One likely pathogenic variant (c.305C>A) was identified in one patient (1.4%). No variant was found in CDK4. Conclusion The prevalence of CDKN2A mutations was 1.4% in Brazilian patients meeting clinical criteria for HM.
doi_str_mv 10.1111/ijd.16742
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2827263169</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2830505439</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3532-db5021f8f4d2253f3136bd0618895f62dfe1e2ae889794a4ff87021a545dde573</originalsourceid><addsrcrecordid>eNp1kctOHDEQRa2IKExIFvkBZIlNsmjGz36wmwxvULJJ1i1Pu0w86sdgu0FkFf6Ab-RLqGFIFkipTamkc6-q6hLyibN9jjX1S7vP80KJN2TCZa4zlUuxRSaMcZ5VTFfb5H2MSxyl4Ood2ZaFFKKUfELu54cX38Rsik3RmEwaI_U9_RrMb99609OVSR76FGkHkHx_RZvW974xLW2CTxC8oW4I9BcEsD6ZcIdga_qhMwfUIDPE-PjnIUKT_NCjykJE4Sr5G6AJ1e0H8taZNsLHl75Dfh4f_ZifZpffT87ms8uskVqKzC40E9yVTlkhtHQSD11YlvOyrLTLhXXAQRjAsaiUUc6VBQqMVtpa0IXcIZ83vqswXI8QU9352ECLy8IwxlqUohC55HmF6N4rdDmMAbdfU5JpppVcU1821PORAVy9Cr7DD9Sc1etcasylfs4F2d0Xx3HRgf1H_g0CgekGuPUt3P3fqT47P9xYPgFFSZe7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2830505439</pqid></control><display><type>article</type><title>CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross‐sectional descriptive trial</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Arnaut, Joyce R. M. B. ; Guimarães, Isabella dos S. ; Santos, Anna Cláudia E. ; Rodrigues, Elizângela M. ; Machado, Jorge R. da S. ; Melo, Andreia C.</creator><creatorcontrib>Arnaut, Joyce R. M. B. ; Guimarães, Isabella dos S. ; Santos, Anna Cláudia E. ; Rodrigues, Elizângela M. ; Machado, Jorge R. da S. ; Melo, Andreia C.</creatorcontrib><description>Background Melanoma is the most lethal skin cancer, and its incidence has increased worldwide. About 10% of cases are classified as hereditary melanoma (HM). CDKN2A and CDK4 are the major high‐risk genes. Families are also more prone to develop pancreatic cancer, and different forms of oncological surveillance are recommended. Objectives Describe the prevalence of CDKN2A/CDK4 germline mutations in melanoma‐prone patients and their phenotypic and histopathological features. Methods A total of 69 patients meeting the clinical criteria for HM were included in this cross‐sectional descriptive study. Amplification by PCR and genomic sequencing were used. The variants were classified according to American College of Medical Genetics (ACMG) criteria. Results The mean age at first diagnosis of melanoma was 44.8 years (SD ± 17.83). Most patients had phototype II (44.9%), more than 50 melanocytic nevi (76.8%), atypical nevus syndrome (72.5%), history of sunburn (76.8%), and multiple primary melanomas without a family history of this tumor (74.3%). Two hundred melanomas were observed. Most tumors had a Breslow index ≤1.0 mm (84.5%), location in the trunk (60.5%), and superficial spreading histological subtype (22.5%). Four variants were found in CDKN2A exons in seven patients (c.305C&gt;A, c.26T&gt;A, c.361G&gt;A e c.442G&gt;A), two variants in the 5′UTR region in five patients (c.‐25C&gt;T and c.‐33G&gt;C), and two variants in the 3′UTR region in 21 patients (c.*29C&gt;G and c.*69C&gt;T). One likely pathogenic variant (c.305C&gt;A) was identified in one patient (1.4%). No variant was found in CDK4. Conclusion The prevalence of CDKN2A mutations was 1.4% in Brazilian patients meeting clinical criteria for HM.</description><identifier>ISSN: 0011-9059</identifier><identifier>EISSN: 1365-4632</identifier><identifier>DOI: 10.1111/ijd.16742</identifier><identifier>PMID: 37322831</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>3' Untranslated regions ; 5' Untranslated Regions ; Adult ; Brazil - epidemiology ; Cancer ; Criteria ; Cross-Sectional Studies ; Cyclin-dependent kinase 4 ; Cyclin-Dependent Kinase 4 - genetics ; Cyclin-Dependent Kinase Inhibitor p16 - genetics ; Exons ; Genetic Predisposition to Disease ; Genetics ; Germ-Line Mutation ; Humans ; Melanoma ; Melanoma - epidemiology ; Melanoma - genetics ; Melanoma - pathology ; Melanoma, Cutaneous Malignant ; Mutation ; Nevus ; Pancreatic cancer ; Patients ; Skin cancer ; Skin Neoplasms - epidemiology ; Skin Neoplasms - genetics ; Skin Neoplasms - pathology ; Sunburn ; Tumors</subject><ispartof>International journal of dermatology, 2023-08, Vol.62 (8), p.1060-1066</ispartof><rights>2023 .</rights><rights>2023 the International Society of Dermatology.</rights><rights>International Journal of Dermatology © 2023 International Society of Dermatology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3532-db5021f8f4d2253f3136bd0618895f62dfe1e2ae889794a4ff87021a545dde573</citedby><cites>FETCH-LOGICAL-c3532-db5021f8f4d2253f3136bd0618895f62dfe1e2ae889794a4ff87021a545dde573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37322831$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arnaut, Joyce R. M. B.</creatorcontrib><creatorcontrib>Guimarães, Isabella dos S.</creatorcontrib><creatorcontrib>Santos, Anna Cláudia E.</creatorcontrib><creatorcontrib>Rodrigues, Elizângela M.</creatorcontrib><creatorcontrib>Machado, Jorge R. da S.</creatorcontrib><creatorcontrib>Melo, Andreia C.</creatorcontrib><title>CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross‐sectional descriptive trial</title><title>International journal of dermatology</title><addtitle>Int J Dermatol</addtitle><description>Background Melanoma is the most lethal skin cancer, and its incidence has increased worldwide. About 10% of cases are classified as hereditary melanoma (HM). CDKN2A and CDK4 are the major high‐risk genes. Families are also more prone to develop pancreatic cancer, and different forms of oncological surveillance are recommended. Objectives Describe the prevalence of CDKN2A/CDK4 germline mutations in melanoma‐prone patients and their phenotypic and histopathological features. Methods A total of 69 patients meeting the clinical criteria for HM were included in this cross‐sectional descriptive study. Amplification by PCR and genomic sequencing were used. The variants were classified according to American College of Medical Genetics (ACMG) criteria. Results The mean age at first diagnosis of melanoma was 44.8 years (SD ± 17.83). Most patients had phototype II (44.9%), more than 50 melanocytic nevi (76.8%), atypical nevus syndrome (72.5%), history of sunburn (76.8%), and multiple primary melanomas without a family history of this tumor (74.3%). Two hundred melanomas were observed. Most tumors had a Breslow index ≤1.0 mm (84.5%), location in the trunk (60.5%), and superficial spreading histological subtype (22.5%). Four variants were found in CDKN2A exons in seven patients (c.305C&gt;A, c.26T&gt;A, c.361G&gt;A e c.442G&gt;A), two variants in the 5′UTR region in five patients (c.‐25C&gt;T and c.‐33G&gt;C), and two variants in the 3′UTR region in 21 patients (c.*29C&gt;G and c.*69C&gt;T). One likely pathogenic variant (c.305C&gt;A) was identified in one patient (1.4%). No variant was found in CDK4. Conclusion The prevalence of CDKN2A mutations was 1.4% in Brazilian patients meeting clinical criteria for HM.</description><subject>3' Untranslated regions</subject><subject>5' Untranslated Regions</subject><subject>Adult</subject><subject>Brazil - epidemiology</subject><subject>Cancer</subject><subject>Criteria</subject><subject>Cross-Sectional Studies</subject><subject>Cyclin-dependent kinase 4</subject><subject>Cyclin-Dependent Kinase 4 - genetics</subject><subject>Cyclin-Dependent Kinase Inhibitor p16 - genetics</subject><subject>Exons</subject><subject>Genetic Predisposition to Disease</subject><subject>Genetics</subject><subject>Germ-Line Mutation</subject><subject>Humans</subject><subject>Melanoma</subject><subject>Melanoma - epidemiology</subject><subject>Melanoma - genetics</subject><subject>Melanoma - pathology</subject><subject>Melanoma, Cutaneous Malignant</subject><subject>Mutation</subject><subject>Nevus</subject><subject>Pancreatic cancer</subject><subject>Patients</subject><subject>Skin cancer</subject><subject>Skin Neoplasms - epidemiology</subject><subject>Skin Neoplasms - genetics</subject><subject>Skin Neoplasms - pathology</subject><subject>Sunburn</subject><subject>Tumors</subject><issn>0011-9059</issn><issn>1365-4632</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp1kctOHDEQRa2IKExIFvkBZIlNsmjGz36wmwxvULJJ1i1Pu0w86sdgu0FkFf6Ab-RLqGFIFkipTamkc6-q6hLyibN9jjX1S7vP80KJN2TCZa4zlUuxRSaMcZ5VTFfb5H2MSxyl4Ood2ZaFFKKUfELu54cX38Rsik3RmEwaI_U9_RrMb99609OVSR76FGkHkHx_RZvW974xLW2CTxC8oW4I9BcEsD6ZcIdga_qhMwfUIDPE-PjnIUKT_NCjykJE4Sr5G6AJ1e0H8taZNsLHl75Dfh4f_ZifZpffT87ms8uskVqKzC40E9yVTlkhtHQSD11YlvOyrLTLhXXAQRjAsaiUUc6VBQqMVtpa0IXcIZ83vqswXI8QU9352ECLy8IwxlqUohC55HmF6N4rdDmMAbdfU5JpppVcU1821PORAVy9Cr7DD9Sc1etcasylfs4F2d0Xx3HRgf1H_g0CgekGuPUt3P3fqT47P9xYPgFFSZe7</recordid><startdate>202308</startdate><enddate>202308</enddate><creator>Arnaut, Joyce R. M. B.</creator><creator>Guimarães, Isabella dos S.</creator><creator>Santos, Anna Cláudia E.</creator><creator>Rodrigues, Elizângela M.</creator><creator>Machado, Jorge R. da S.</creator><creator>Melo, Andreia C.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>202308</creationdate><title>CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross‐sectional descriptive trial</title><author>Arnaut, Joyce R. M. B. ; Guimarães, Isabella dos S. ; Santos, Anna Cláudia E. ; Rodrigues, Elizângela M. ; Machado, Jorge R. da S. ; Melo, Andreia C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3532-db5021f8f4d2253f3136bd0618895f62dfe1e2ae889794a4ff87021a545dde573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>3' Untranslated regions</topic><topic>5' Untranslated Regions</topic><topic>Adult</topic><topic>Brazil - epidemiology</topic><topic>Cancer</topic><topic>Criteria</topic><topic>Cross-Sectional Studies</topic><topic>Cyclin-dependent kinase 4</topic><topic>Cyclin-Dependent Kinase 4 - genetics</topic><topic>Cyclin-Dependent Kinase Inhibitor p16 - genetics</topic><topic>Exons</topic><topic>Genetic Predisposition to Disease</topic><topic>Genetics</topic><topic>Germ-Line Mutation</topic><topic>Humans</topic><topic>Melanoma</topic><topic>Melanoma - epidemiology</topic><topic>Melanoma - genetics</topic><topic>Melanoma - pathology</topic><topic>Melanoma, Cutaneous Malignant</topic><topic>Mutation</topic><topic>Nevus</topic><topic>Pancreatic cancer</topic><topic>Patients</topic><topic>Skin cancer</topic><topic>Skin Neoplasms - epidemiology</topic><topic>Skin Neoplasms - genetics</topic><topic>Skin Neoplasms - pathology</topic><topic>Sunburn</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arnaut, Joyce R. M. B.</creatorcontrib><creatorcontrib>Guimarães, Isabella dos S.</creatorcontrib><creatorcontrib>Santos, Anna Cláudia E.</creatorcontrib><creatorcontrib>Rodrigues, Elizângela M.</creatorcontrib><creatorcontrib>Machado, Jorge R. da S.</creatorcontrib><creatorcontrib>Melo, Andreia C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arnaut, Joyce R. M. B.</au><au>Guimarães, Isabella dos S.</au><au>Santos, Anna Cláudia E.</au><au>Rodrigues, Elizângela M.</au><au>Machado, Jorge R. da S.</au><au>Melo, Andreia C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross‐sectional descriptive trial</atitle><jtitle>International journal of dermatology</jtitle><addtitle>Int J Dermatol</addtitle><date>2023-08</date><risdate>2023</risdate><volume>62</volume><issue>8</issue><spage>1060</spage><epage>1066</epage><pages>1060-1066</pages><issn>0011-9059</issn><eissn>1365-4632</eissn><abstract>Background Melanoma is the most lethal skin cancer, and its incidence has increased worldwide. About 10% of cases are classified as hereditary melanoma (HM). CDKN2A and CDK4 are the major high‐risk genes. Families are also more prone to develop pancreatic cancer, and different forms of oncological surveillance are recommended. Objectives Describe the prevalence of CDKN2A/CDK4 germline mutations in melanoma‐prone patients and their phenotypic and histopathological features. Methods A total of 69 patients meeting the clinical criteria for HM were included in this cross‐sectional descriptive study. Amplification by PCR and genomic sequencing were used. The variants were classified according to American College of Medical Genetics (ACMG) criteria. Results The mean age at first diagnosis of melanoma was 44.8 years (SD ± 17.83). Most patients had phototype II (44.9%), more than 50 melanocytic nevi (76.8%), atypical nevus syndrome (72.5%), history of sunburn (76.8%), and multiple primary melanomas without a family history of this tumor (74.3%). Two hundred melanomas were observed. Most tumors had a Breslow index ≤1.0 mm (84.5%), location in the trunk (60.5%), and superficial spreading histological subtype (22.5%). Four variants were found in CDKN2A exons in seven patients (c.305C&gt;A, c.26T&gt;A, c.361G&gt;A e c.442G&gt;A), two variants in the 5′UTR region in five patients (c.‐25C&gt;T and c.‐33G&gt;C), and two variants in the 3′UTR region in 21 patients (c.*29C&gt;G and c.*69C&gt;T). One likely pathogenic variant (c.305C&gt;A) was identified in one patient (1.4%). No variant was found in CDK4. Conclusion The prevalence of CDKN2A mutations was 1.4% in Brazilian patients meeting clinical criteria for HM.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>37322831</pmid><doi>10.1111/ijd.16742</doi><tpages>1066</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0011-9059
ispartof International journal of dermatology, 2023-08, Vol.62 (8), p.1060-1066
issn 0011-9059
1365-4632
language eng
recordid cdi_proquest_miscellaneous_2827263169
source Wiley-Blackwell Read & Publish Collection
subjects 3' Untranslated regions
5' Untranslated Regions
Adult
Brazil - epidemiology
Cancer
Criteria
Cross-Sectional Studies
Cyclin-dependent kinase 4
Cyclin-Dependent Kinase 4 - genetics
Cyclin-Dependent Kinase Inhibitor p16 - genetics
Exons
Genetic Predisposition to Disease
Genetics
Germ-Line Mutation
Humans
Melanoma
Melanoma - epidemiology
Melanoma - genetics
Melanoma - pathology
Melanoma, Cutaneous Malignant
Mutation
Nevus
Pancreatic cancer
Patients
Skin cancer
Skin Neoplasms - epidemiology
Skin Neoplasms - genetics
Skin Neoplasms - pathology
Sunburn
Tumors
title CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross‐sectional descriptive trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T19%3A28%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CDKN2A/CDK4%20status%20in%20Brazilian%20patients%20meeting%20clinical%20criteria%20for%20hereditary%20melanoma:%20a%20cross%E2%80%90sectional%20descriptive%20trial&rft.jtitle=International%20journal%20of%20dermatology&rft.au=Arnaut,%20Joyce%20R.%20M.%20B.&rft.date=2023-08&rft.volume=62&rft.issue=8&rft.spage=1060&rft.epage=1066&rft.pages=1060-1066&rft.issn=0011-9059&rft.eissn=1365-4632&rft_id=info:doi/10.1111/ijd.16742&rft_dat=%3Cproquest_cross%3E2830505439%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3532-db5021f8f4d2253f3136bd0618895f62dfe1e2ae889794a4ff87021a545dde573%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2830505439&rft_id=info:pmid/37322831&rfr_iscdi=true